Application of Omics and Bioinformatics Technologies in Response to COVID-19 Pandemic
Abstract
The medical biotechnology community has undertaken significant endeavors to gain a comprehensive understanding of SARS-CoV-2’s biology and pathogenesis mechanisms. Omics approaches and technologies have been widely employed in the fight against SARS-CoV-2. Since the onset of the virus outbreak, researchers have demonstrated how recent omics and bioinformatics technological advancements have contributed to the diagnosis, vaccine development, treatment, and control of disease transmission. Studies conducted since the outbreak have been collected and summarized, with a focus on bioinformatics approaches and their contribution to controlling this pandemic. Developments and advanced omics technology in connection to the COVID-19 pandemic have been analyzed. The multi-omics technology, which offers various strategies in identifying potential diagnostics, therapeutics, studies of variants of concern, and drug repurposing approaches, has been assessed. Pandemic response has seen the application of multi-omics and pan-genomics approaches, including genomics, metabolomics, transcriptomics, proteomics, epigenomics, clustered regularly interspaced short palindromic repeats (CRISPR) technology, host-pathogen interactions, artificial intelligence, and machine learning in various research areas. Additionally, bioinformatics and mathematical modeling have played a significant role in disease control. The use of smart technologies to control virus transmission and predict patients’ health conditions and treatment outcomes has also been crucial. Transcriptome analysis has emerged as a major application, contributing to the generation of new knowledge on viral sequences and intracellular signaling pathways that regulate viral infection and pathogenesis mechanisms. The sequencing of the virus has paved the way for the use of omics technologies and an integrative technique in combating the pandemic. In general, the advancement of omics technology during this pandemic has been fascinating and has contributed a significant role to the science of health biotechnology in general and omics and bioinformatics in particular.
Keywords: bioinformatics, coronavirus, COVID-19, omics, SARS COV-2
Full Text:
PDFReferences
Padhi AK, Dandapat J, Saudagar P, Uversky VN, Tripathi T. Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination. FEBS Lett. 2021; 595(18): 2366-82, CrossRef.
Candido DS, Claro IM, de Jesus JG, Souza WM, Moreira FRR, Dellicour S, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science. 2020; 369(6508): 1255-60, CrossRef.
Fagone P, Ciurleo R, Lombardo SD, Iacobello C, Palermo CI, Shoenfeld Y, et al. Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. Autoimmun Rev. 2020; 19(7): 102571, CrossRef.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-3, CrossRef.
Feng L, Yin YY, Liu CH, Xu KR, Li QR, Wu JR, et al. Proteome-wide data analysis reveals tissue-specific network associated with SARS-CoV-2 infection. J Mol Cell Biol. 2020; 12(12): 946-57, CrossRef.
Arriaga-Canon C, Contreras-Espinosa L, Rebollar-Vega R, Montiel-Manríquez R, Cedro-Tanda A, García-Gordillo JA, et al. Transcriptomics and RNA-based therapeutics as potential approaches to manage SARS-CoV-2 infection. Int J Mol Sci. 2022; 23(19): 11058, CrossRef.
Liu B, Liu K, Zhang H, Zhang L, Bian Y, Huang L. CoV-Seq, a new tool for SARS-CoV-2 genome analysis and visualization: Development and usability study. J Med Internet Res. 2020; 22(10): e22299, CrossRef.
Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci. 2020; 6(5): 591-605, CrossRef.
Aschenbrenner AC, Mouktaroudi M, Krämer B, Oestreich M, Antonakos N, Nuesch-Germano M, et al. Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. Genome Med. 2021; 13(1): 7, CrossRef.
Bell LCK, Meydan C, Kim J, Foox J, Butler D, Mason CE, et al. Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19. iScience. 2021; 24(1): 101896, CrossRef.
Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N Engl J Med. 2021; 385(7): 664-6, CrossRef.
Turilli ES, Lualdi M, Fasano M. Looking at COVID-19 from a systems biology perspective. Biomolecules. 2022; 12(2): 188, CrossRef.
Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021; 184(9): 2348-61.e6, CrossRef.
Cen X, Wang F, Huang X, Jovic D, Dubee F, Yang H, et al. Towards precision medicine: Omics approach for COVID-19. Biosaf Health. 2023; 5(2): 78-88, CrossRef.
Diray-Arce J, Conti MG, Petrova B, Kanarek N, Angelidou A, Levy O. Integrative metabolomics to identify molecular signatures of responses to vaccines and infections. Metabolites. 2020; 10(12): 492, CrossRef.
Li CX, Gao J, Zhang Z, Chen L, Li X, Zhou M, et al. Multiomics integration-based molecular characterizations of COVID-19. Brief Bioinform. 2022; 23(1): bbab485, CrossRef.
Zhou Y, Zhang L, Xie YH, Wu J. Advancements in detection of SARS-CoV-2 infection for confronting COVID-19 pandemics. Lab Invest. 2022; 102(1): 4-13, CrossRef.
Wu C, Qavi AJ, Hachim A, Kavian N, Cole AR, Moyle AB, et al. Characterization of SARS-CoV-2 nucleocapsid protein reveals multiple functional consequences of the C-terminal domain. iScience. 2021; 24(6): 102681, CrossRef.
Tsang NNY, So HC, Ng KY, Cowling BJ, Leung GM, Ip DKM. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: A systematic review and meta-analysis. Lancet Infect Dis. 2021; 21(9): 1233-45, CrossRef.
Tandirogang N, Fitriany E, Mardania N, Jannah M, Dilan, BFN, Ratri SR, et al. Neutralizing antibody response by inactivated SARS-CoV-2 vaccine on healthcare workers. Mol Cell Biomed Sci. 2023. 7(1): 18-27, CrossRef.
Armimi A, Syuaib AF, Vanya K, Tan MI, Natalia D, Chen DV, et al. SARS-CoV-2 neutralization assay system using pseudo-lentivirus. Indones Biomed J. 2023; 15(2): 179-86, CrossRef.
Belfiore MP, Urraro F, Grassi R, Giacobbe G, Patelli G, Cappabianca S, et al. Artificial intelligence to codify lung CT in Covid-19 patients. Radiol Med. 2020;125(5):500-4, CrossRef.
Infusino F, Marazzato M, Mancone M, Fedele F, Mastroianni CM, Severino P, et al. Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection: A scoping review. Nutrients. 2020; 12(6): 1718, CrossRef.
Sameh M, Khalaf HM, Anwar AM, Osama A, Ahmed EA, Mahgoub S, et al. Integrated multiomics analysis to infer COVID-19 biological insights. Sci Rep. 2023; 13(1): 1802. doi: 10.1038/s41598-023-28816-5, CrossRef.
Wadapurkar RM, Vyas R. Computational analysis of next generation sequencing data and its applications in clinical oncology. Informatics Med Unlocked. 2018; 11: 75-82, CrossRef.
Bojkova D, Klann K, Koch B, Widera M, Krause D, Ciesek S, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020; 583(7816): 469-72, CrossRef.
Tablizo FA, Kim KM, Lapid CM, Castro MJ, Yangzon MS, Maralit BA, et al. Genome sequencing and analysis of an emergent SARS-CoV-2 variant characterized by multiple spike protein mutations detected from the Central Visayas Region of the Philippines [Preprint]. medRxiv. 2021; n.v: 2021.03.03.21252812, CrossRef.
Calina D, Hernández AF, Hartung T, Egorov AM, Izotov BN, Nikolouzakis TK, et al. Challenges and scientific prospects of the newest generation of mRNA-based vaccines against SARS-CoV-2. Life. 2021; 11(9): 907, CrossRef.
Wang Y, Jiang W, He Q, Wang C, Liu B, Zhou P, et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: Single-center experience from Wuhan, China [Preprint]. medRxiv. 2020; n.v: 2020.03.06.20032342, CrossRef.
Wu A, Wang L, Zhou HY, Ji CY, Xia SZ, Cao Y, et al. One year of SARS-CoV-2 evolution. Cell Host Microbe. 2021; 29(4): 503-7, CrossRef.
Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelli S, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 2021; 35(13): 109292, CrossRef.
Zhou B, Thao TTN, Hoffmann D, Taddeo A, Ebert N, Labroussaa F, et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature. 2021; 592(7852): 122-7, CrossRef.
Yuliawuri H, Christian JE, Steven N. Non-synonymous mutation analysis of SARS-CoV-2 ORF3a in Indonesia. Mol Cell Biomed Sci. 2022; 6(1): 20-7, CrossRef.
Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020; 63(3):457-60, CrossRef.
Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, COVID-19 Genomics UK Consortium, et al. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat Rev Microbiol. 2023; 21(3): 162-77, CrossRef.
Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. 2020; 81: 104260, CrossRef.
Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell. 2021; 184(10): 2587-94.e7, CrossRef.
Darby AC, Hiscox JA. Covid-19: Variants and vaccination. BMJ. 2021; 372: n771, CrossRef.
Van Noorden R. Scientists call for fully open sharing of coronavirus genome data. Nature. 2021; 590(7845): 195-6, CrossRef.
Hwang B, Lee JH, Bang D. Single-cell RNA sequencing technologies and bioinformatics pipelines. Exp Mol Med. 2018; 50(8): 1-14, CrossRef.
Nagano K, Tani-Sassa C, Iwasaki Y, Takatsuki Y, Yuasa S, Takahashi Y, et al. SARS-CoV-2 R.1 lineage variants that prevailed in Tokyo in March 2021. J Med Virol. 2021; 93(12): 6833-6, CrossRef.
Tegally H, Wilkinson E, Lessells RJ, Giandhari J, Pillay S, Msomi N, et al. Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat Med. 2021; 27(3): 440-6, CrossRef.
Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017; 8: 14049. doi: 10.1038/ncomms14049, CrossRef.
Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021; 372(6544): 815-21, CrossRef.
Resende PC, Bezerra JF, Teixeira Vasconcelos RH, Arantes I, Appolinario L, Mendonça AC, et al. Severe acute respiratory syndrome coronavirus 2 P.2 lineage associated with reinfection case, Brazil, June-October 2020. Emerg Infect Dis. 2021; 27(7): 1789-94, CrossRef.
Wyman D, Balderrama-Gutierrez G, Reese F, Jiang S, Rahmanian S, Forner S, et al. A technology-agnostic long-read analysis pipeline for transcriptome discovery and quantification [Preprint]. bioRxiv. 2019; n.v: 672931, CrossRef.
Vacca D, Fiannaca A, Tramuto F, Cancila V, La Paglia L, Mazzucco W, et al. Direct RNA nanopore sequencing of SARS-CoV-2 extracted from critical material from swabs. Life. 2022; 12(1): 69, CrossRef.
Pillay S, Giandhari J, Tegally H, Wilkinson E, Chimukangara B, Lessells R, et al. Whole genome sequencing of SARS-CoV-2: Adapting Illumina protocols for quick and accurate outbreak investigation during a pandemic. Genes. 2020; 11(8): 949, CrossRef.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7): 934-43, CrossRef.
Spratt AN, Kannan SR, Woods LT, Weisman GA, Quinn TP, Lorson CL, et al. Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. Comput Struct Biotechnol J. 2021; 19: 3799-809, CrossRef.
Mansbach RA, Chakraborty S, Nguyen K, Montefiori DC, Korber B, Gnanakaran S. The SARS-CoV-2 Spike variant D614G favors an open conformational state. Sci Adv. 2021; 7(16): eabf3671, CrossRef.
Naveca FG, Nascimento V, de Souza VC, Corado AL, Nascimento F, Silva G, et al. COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. Nat Med. 2021; 27(7): 1230-8, CrossRef.
Hodcroft EB, De Maio N, Lanfear R, MacCannell DR, Minh BQ, Schmidt HA, et al. Want to track pandemic variants faster? Fix the bioinformatics bottleneck. Nature. 2021; 591(7848): 30-3, CrossRef.
Niu Z, Zhang Z, Gao X, Du P, Lu J, Yan B, et al. N501Y mutation imparts cross-species transmission of SARS-CoV-2 to mice by enhancing receptor binding. Signal Transduct Target Ther. 2021; 6(1): 284, CrossRef.
Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021; 29(5): 747-51.e4, CrossRef.
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581(7807): 215-20, CrossRef.
Borkotoky S, Banerjee M. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem). J Biomol Struct Dyn. 2021; 39(11): 4111-21, CrossRef.
Lemieux JE, Siddle KJ, Shaw BM, Loreth C, Schaffner SF, Gladden-Young A, et al. Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events. Science. 2021; 371(6529): eabe3261, CrossRef.
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020; 582(7811): 289-93, CrossRef.
Barberis E, Timo S, Amede E, Vanella VV, Puricelli C, Cappellano G, et al. Large-scale plasma analysis revealed new mechanisms and molecules associated with the host response to SARS-CoV-2. Int J Mol Sci. 2020; 21(22): 8623, CrossRef.
Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021; 371(6531): 850-4, CrossRef.
Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021; 184(5): 1171-87.e20, CrossRef.
Kemp SA, Collier DA, Datir RP, Ferreira IA, Gayed S, Jahun A, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021; 592(7853): 277-82, CrossRef.
Choudhary S, Sharma K, Singh PK. Von Willebrand factor: A key glycoprotein involved in thrombo-inflammatory complications of COVID-19. Chem Biol Interact. 2021; 348: 109657, CrossRef.
Martins AF, Zavascki AP, Wink PL, Volpato FCZ, Monteiro FL, Rosset C, et al. Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalisation rate, February 2021, Rio Grande do Sul, Southern Brazil. Euro Surveill. 2021; 26(12): 2100276, CrossRef.
Niture S, Lin M, Rios-Colon L, Qi Q, Moore JT, Kumar D. Emerging roles of impaired autophagy in fatty liver disease and hepatocellular carcinoma. Int J Hepatol. 2021; 2021: 6675762, CrossRef.
Singh R, Singh PK, Kumar R, Kabir MT, Kamal MA, Rauf A, et al. Multi-omics approach in the identification of potential therapeutic biomolecule for COVID-19. Front Pharmacol. 2021; 12: 652335, CrossRef.
Tayara H, Abdelbaky I, To Chong K. Recent omics-based computational methods for COVID-19 drug discovery and repurposing. Brief Bioinform. 2021; 22(6): bbab339, CrossRef.
Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O'Toole Á, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell. 2021; 184(1): 64-75.e11, CrossRef.
Jain R, Ramaswamy S, Harilal D, Uddin M, Loney T, Nowotny N, et al. Host transcriptomic profiling of COVID-19 patients with mild, moderate, and severe clinical outcomes. Comput Struct Biotechnol J. 2020; 19: 153-60, CrossRef.
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov. 2019; 18(1): 41-58, CrossRef.
Chitalia VC, Munawar AH. A painful lesson from the COVID-19 pandemic: The need for broad-spectrum, host-directed antivirals. J Transl Med. 2020; 18(1): 390, CrossRef.
Menzella F, Biava M, Barbieri C, Livrieri F, Facciolongo N. Pharmacological treatment of COVID-19: Lights and shadows. Drugs Context. 2020; 9: 2020-4-6, CrossRef.
O'Donovan SM, Imami A, Eby H, Henkel ND, Creeden JF, Asah S, et al. Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach. Sci Rep. 2021 Feb 24;11(1):4495, CrossRef.
Ospina-Tascón GA, Calderón-Tapia LE, García AF, Zarama V, Gómez-Álvarez F, Álvarez-Saa T, et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: A randomized clinical trial. JAMA. 2021; 326(21): 2161-71, CrossRef.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering. 2020; 6(10): 1192-8, CrossRef.
Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020; 38(4): 379-81, CrossRef.
Yu F, Pan T, Huang F, Ying R, Liu J, Fan H, et al. Glycopeptide antibiotic teicoplanin inhibits cell entry of SARS-CoV-2 by suppressing the proteolytic activity of cathepsin L. Front Microbiol. 2022; 13: 884034, CrossRef.
Bonzano C, Borroni D, Lancia A, Bonzano E. Doxycycline: From ocular rosacea to COVID-19 Anosmia. New insight into the Coronavirus outbreak. Front Med. 2020; 7: 200, CrossRef.
DOI: https://doi.org/10.21705/mcbs.v8i1.363
Copyright (c) 2024 Cell and BioPharmaceutical Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
Cell and BioPharmaceutical Institute
